Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for polymyalgia rheumatica
ChiCTR2000038253Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib in polymyalgia rheumatica (PMR) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Proportion of patients with PMR-AS < 10 at 24 weeks. Started Sep 2020; status: recruiting.
02
Drugs
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on ChiCTR2000038253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038253.